Aileron Therapeutics, Inc.
ALRN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $41,259 | $14,026 | $10,758 | $49,998 |
| - Cash | $12,865 | $17,313 | $5,194 | $3,600 |
| + Debt | $0 | $48 | $33 | $162 |
| Enterprise Value | $28,394 | -$3,239 | $5,597 | $46,560 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$119 | -$169 | -$121 |
| % Margin | – | – | – | – |
| EBITDA | -$65,112 | -$15,613 | -$27,478 | -$26,484 |
| % Margin | – | – | – | – |
| Net Income | -$62,883 | -$15,732 | -$27,011 | -$25,764 |
| % Margin | – | – | – | – |
| EPS Diluted | -3.51 | -3.42 | -5.95 | -5.8 |
| % Growth | -2.6% | 42.5% | -2.6% | – |
| Operating Cash Flow | -$22,291 | -$19,808 | -$24,865 | -$23,754 |
| Capital Expenditures | $0 | $0 | $0 | -$157 |
| Free Cash Flow | -$22,291 | -$19,808 | -$24,865 | -$23,911 |